COVID-19 et cancer bronchique : adaptation des schémas d’immunothérapie et qualité de vie

INTRODUCTION: COVID-19 pandemics required changes in medical practices. In thoracic oncology, pembrolizumab was doubled to 400 mg every 6 weeks, nivolumab to 480 mg every 4 weeks. The objective of our study was to assess the impact on quality of life, and on psychological state, as well as the toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Travert, C., Cannone, P., Greillier, L., Tomasini, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SPLF. Published by Elsevier Masson SAS. 2021
Materias:
Article Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241593/
https://www.ncbi.nlm.nih.gov/pubmed/34246519
http://dx.doi.org/10.1016/j.rmr.2021.06.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241593/
https://www.ncbi.nlm.nih.gov/pubmed/34246519
http://dx.doi.org/10.1016/j.rmr.2021.06.005

Ejemplares similares